Yang et al. designed tumor-targeting nanoparticles (CS-HAP@ATO NPs) by loading atorvastatin (ATO) onto chondroitin sulfate-modified hydroxyapatite nanoparticles (CS-HAP), which mediate inflammatory damage through the NLRP3- caspase-1- GSDMD pathway [221]. Here, GSDMD is linked to neoplasm.